2023-05-11 17:04:41来源：美国临床肿瘤学会（ASCO）年会阅读：39次
一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，头颈部肿瘤领域Poster Session中国共入选20项研究。期待中国专家在ASCO年会上展现风采！
头颈部肿瘤
Head and Neck Cancer
摘要号: 6024
标题：Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: A recursive partitioning risk stratification analysis.
报告人: 孔芳芳
单位：复旦大学附属肿瘤医院
摘要号: 6026
标题：A phase Ib/II study of GFH018 in combination with toripalimab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).
报告人：麦海强
单位：中山大学肿瘤防治中心
摘要号: 6030
标题：Influence of widely targeted quantitative lipidomics on plasma lipid predictors and pathway dysregulation for nasopharyngeal carcinoma.
报告人：陈曦
单位：中山大学肿瘤防治中心
摘要号: 6031
标题：Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: An open-label phase II study.
报告人：Nian Lu
单位：中山大学肿瘤防治中心
摘要号: 6037
标题：Results from two phase II studies of SI-B001, an EGFR×HER3 bispecific antibody, with/without chemotherapy in patients (pts) with recurrent and metastatic head and neck squamous cell carcinoma (HNSCC).
报告人：薛丽琼
单位：同济大学附属东方医院
摘要号: 6047
标题：TCR-T cells armored with immune checkpoint blockade in EBV-positive nasopharyngeal carcinoma: The first-in-human phase 1/2 trial.
报告人：Ling Peng
单位：广东天科雅生物医药科技有限公司
摘要号: 6049
标题：Low-dose fractionated radiotherapy combined with neoadjuvant chemotherapy for T3-4 nasopharyngeal carcinoma patients: Preliminary results of a phase II randomized controlled trial.
报告人：冯梅
单位：四川省肿瘤医院
摘要号: 6064
标题：Radiotherapy alone versus concurrent or adjuvant chemoradiotherapy for nasopharyngeal carcinoma patients with negative Epstein-Barr virus DNA post-induction chemotherapy.
报告人：孔芳芳
单位：复旦大学附属肿瘤医院
摘要号: 6067
标题：Induction chemotherapy with nedaplatin, docetaxel and 5-fluorouracil followed by concurrent nedaplatin and radiotherapy in locoregionally advanced nasopharyngeal carcinoma: A single arm, open label, phase II clinical trial.
报告人：Chen Fangzheng
单位：广州医科大学附属肿瘤医院
摘要号: 6068
标题：Induction chemotherapy and toripalimab for larynx preservation in resectable locally advanced laryngeal/hypopharyngeal carcinoma: Preliminary results of INSIGHT study.
报告人：区晓敏
单位：复旦大学附属肿瘤医院
摘要号: 6069
标题：A pilot phase II trial of neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin (NeoCPC) for locoregionally advanced, resectable squamous cell carcinoma of the head and neck.
报告人：Di Wu
单位：中山大学肿瘤防治中心
摘要号: 6070
标题：Induction therapy of toripalimab combined with docetaxel and cisplatin in locally advanced hypopharyngeal squamous cell carcinoma (HPSCC): A single-arm, phase II clinical trial.
报告人：白春梅
单位：北京协和医院
摘要号: 6071
标题：Nab-paclitaxel plus cisplatin versus docetaxel plus cisplatin and 5-FU induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: A multicenter parallel controlled phase III trial.
报告人：吕星
单位：中山大学肿瘤防治中心
摘要号: 6072
标题：Prospective study of integrating post-radiotherapy [18F] fluorodeoxyglucose-positron emission tomography/computed tomography scan and plasma Epstein-Barr virus DNA in surveillance of locoregionally advanced nasopharyngeal carcinoma.
报告人：唐林泉
单位：中山大学肿瘤防治中心
摘要号: 6077
标题：Neoadjuvant chemoimmunotherapy for the treatment of locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: A single-arm phase 2 clinical trial.
报告人：陈艳峰
单位：中山大学肿瘤防治中心
摘要号: 6078
标题：Neoadjuvant low-dose radiotherapy, tislelizumab, combined with albumin-bound paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoRTPC02): The first-stage result from an open label, single-arm, two stage, phase II clinical trial.
报告人：刘志刚
单位：南方医科大学附属东莞医院肿瘤中心
摘要号: 6080
标题：Neoadjuvant tislelizumab combined with APF for patients with locally advanced head and neck squamous cell carcinoma: A prospective single-arm clinical trial.
报告人：闫婧
单位：南京大学医学院附属鼓楼医院
摘要号: 6087
标题：Tislelizumab plus chemotherapy as induction treatment followed by chemoradiotherapy or surgery in locally advanced hypopharyngeal squamous cell carcinoma: A single-arm, phase II trial.
报告人：桂琳
单位：中国医学科学院附属肿瘤医院
摘要号: 6089
标题：A multicenter, single-arm phase 2 study of surufatinib plus toripalimab for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.
报告人：季冬梅
单位：复旦大学附属肿瘤医院
摘要号: TPS6112
标题：Response-adapted therapy for locally advanced nasopharyngeal carcinoma based on clinical response and circulating Epstein-Barr virus DNA level post induction chemotherapy.
报告人：胡超苏
单位：复旦大学附属肿瘤医院
备注：排名不分先后，按照摘要号进行
如有遗漏或任何问题，请给我们留言~